Package Leaflet: Information for the Patient
AJOVY 225mg solution for injection in pre-filled pen
fremanezumab
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
What is AJOVY
AJOVY is a medicine that contains the active substance fremanezumab, a monoclonal antibody, a type of protein that recognizes and binds to a specific target in the body.
How AJOVY works
A substance in the body called calcitonin gene-related peptide (CGRP) plays an important role in migraine. Fremanezumab binds to CGRP and prevents it from working. This reduction in CGRP activity reduces migraine attacks.
What AJOVY is used for
AJOVY is used to prevent migraine in adults with at least 4 days of migraine per month.
What are the benefits of using AJOVY
AJOVY reduces the frequency of migraine attacks and the number of days with headache. This medicine also reduces the disability associated with migraine and decreases the need to use medicines to treat migraine attacks.
Do not use AJOVY
Do not use this medicine if you are allergic to fremanezumab or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Tell your doctor, pharmacist, or nurse immediately if you notice any signs of a severe allergic reaction such as breathing problems, swelling of the lips and tongue, or severe skin rash after injection of AJOVY. These reactions can occur within 24 hours after administration of AJOVY, although they can sometimes appear later.
Tell your doctor if you have or have had any cardiovascular disease (problems affecting the heart and blood vessels) before starting to use this medicine, as AJOVY has not been studied in patients with certain cardiovascular diseases.
Children and adolescents
AJOVY is not recommended for use in children and adolescents under 18 years of age, as it has not been studied in this age group.
Other medicines and AJOVY
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Pregnancy and breastfeeding
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. It is preferable to avoid using AJOVY during pregnancy, as the effects of this medicine on pregnant women are unknown.
If you are breastfeeding or plan to breastfeed, consult your doctor or pharmacist before starting to use this medicine. You and your doctor will decide whether to use AJOVY during breastfeeding.
Driving and using machines
This medicine is not expected to have any effect on your ability to drive and use machines.
AJOVY contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Read carefully the "Instructions for use" of the pre-filled pen before starting to use AJOVY.
How much and when to inject
Your doctor will discuss and decide with you the most suitable dosage regimen. There are two alternative dosage regimens recommended:
If your dose is 675 mg, administer the three injections one after the other, in a different place each time.
AJOVY is administered by injection under the skin (subcutaneous injection). Your doctor or nurse will explain to you or your caregiver how to administer the injection. Do not inject AJOVY until your doctor or nurse has taught you or your caregiver how to do it.
Use some reminder method, such as notes on a calendar or diary, to help you remember the next dose and not miss a dose or inject a dose too soon after the last one.
If you use more AJOVY than you should
If you have used more AJOVY than you should, consult your doctor.
If you miss a dose of AJOVY
If you have missed a dose of AJOVY, inject the missed dose as soon as possible. Do not administer a double dose to make up for missed doses. If you are unsure when you should inject AJOVY, consult your doctor, pharmacist, or nurse.
If you have any other questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects may occur:
Very common (may affect more than 1 in 10 people)
Pain, hardening, or redness at the injection site
Common (may affect up to 1 in 10 people)
Itching at the injection site
Uncommon (may affect up to 1 in 100 people)
Skin rash at the injection site
Allergic reactions such as exanthema, swelling, or urticaria
Rare (may affect up to 1 in 1,000 people)
Severe allergic reactions (signs may be breathing problems, swelling of the lips and tongue, or severe skin rash) (see section 2 "Warnings and precautions").
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label of the pen and on the outer packaging after "EXP". The expiry date is the last day of the month shown.
Store in a refrigerator (between 2°C and 8°C). Do not freeze.
Keep the pre-filled pen in the outer packaging to protect the medicine from light.
This medicine can be taken out of the refrigerator and stored at a temperature not above 30°C for a maximum period of 7 days. The medicine should be discarded if it has been out of the refrigerator for more than 7 days. Once stored at room temperature, do not put it back in the refrigerator.
Do not use this medicine if you notice that the outer packaging has been tampered with, the pen is damaged, or the medicine is cloudy, has changed color, or contains particles.
The pen is for single use.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
AJOVY Composition
Each pre-filled pen contains 225 mg of fremanezumab.
Product Appearance and Container Contents
AJOVY is an injectable solution in a single-dose pre-filled pen. AJOVY is a clear, colorless to slightly yellow solution. Each pre-filled pen contains 1.5 ml of solution.
AJOVY is available in packs containing 1 or 3 pre-filled pens. Not all pack sizes may be available in your country.
Marketing Authorization Holder
TEVA GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany
Manufacturer
Merckle GmbH
Graf-Arco-Str. 3
89079 Ulm
Germany
Teva Pharmaceuticals Europe B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
You can request more information about this medicinal product from the local representative of the marketing authorization holder.
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A./AG Tél/Tel: +32 38207373 | Lietuva UAB Teva Baltics Tel: +370 52660203 |
България Тева Фарма ЕООД Тел: +359 24899585 | Luxembourg/Luxemburg Teva Pharma Belgium N.V./S.A./AG Belgique/Belgien Tél/Tel: +32 38207373 |
Česká republika Teva Pharmaceuticals CR, s.r.o. Tel: +420 251007111 | Magyarország Teva Gyógyszergyár Zrt. Tel: +36 12886400 |
Danmark Teva Denmark A/S Tlf: +45 44985511 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Deutschland TEVA GmbH Tel: +49 73140208 | Nederland Teva Nederland B.V. Tel: +31 8000228400 |
Eesti UAB Teva Baltics Eesti filiaal Tel: +372 6610801 | Norge Teva Norway AS Tlf: +47 66775590 |
Ελλάδα ΤΕΒΑ ΕΛΛΑΣ Α.Ε. Τηλ: +30 2118805000 | Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1970070 |
España Teva Pharma, S.L.U. Tel: +34 913873280 | Polska Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 223459300 |
France Teva Santé Tél: +33 155917800 | Portugal Teva Pharma - Produtos Farmacêuticos, Lda. Tel: +351 214767550 |
Hrvatska Pliva Hrvatska d.o.o. Tel: +385 13720000 | România Teva Pharmaceuticals S.R.L. Tel: +40 212306524 |
Ireland Teva Pharmaceuticals Ireland Tel: +44 2075407117 | Slovenija Pliva Ljubljana d.o.o. Tel: +386 15890390 |
Ísland Teva Pharma Iceland ehf. Sími: +354 5503300 | Slovenská republika TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257267911 |
Italia Teva Italia S.r.l. Tel: +39 028917981 | Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805900 |
Κύπρος ΤΕΒΑ ΕΛΛΑΣ Α.Ε. Ελλάδα Τηλ: +30 2118805000 | Sverige Teva Sweden AB Tel: +46 42121100 |
Latvija UAB Teva Baltics filiale Latvija Tel: +371 67323666 | United Kingdom (Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 2075407117 |
Date of Last Revision of this Leaflet:{Month YYYY}.
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency web site: http://www.ema.europa.eu.
------------------------------------------------------------------------------------------------------------------------
Instructions for Use
AJOVY 225 mg Solution for Injection in Pre-filled Pen
fremanezumab
Before Using the AJOVY Pre-filled Pen, Read and Follow the Instructions Carefully Step by Step.
Important Information:
AJOVY Pre-filled Pen (Before Use)
AJOVY Pre-filled Pen (After Use)
Step 1: Preparation for Injection
Step 2: How to Inject
|
|
|
Step 3: Disposal of the Pre-filled Pen
If Your Dose is 675 mg, Repeat Steps 1 to 3 with the Second and Third Pre-filled Pens to Administer the Full Dose.